Health-related quality of life assessment in the marketing authorization application of anticancer drugs in Europe

Ramon Van Poppel, Jacqueline Müller-Nordhorn, Wolf-Dieter Ludwig & Gisela Schott
Background: Since 1995, for each anticancer drug registered in Europe following the so called Centralized Procedure, an “European Public Assessment Report” (EPAR) is made available by the European Medicines Agency (EMA). Especially for anticancer drugs, the impact of the drug on health-related[for full text, please go to the a.m. URL]